We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Breath Test Could Help Detect Blood Cancers

By LabMedica International staff writers
Posted on 24 Jul 2025

Blood cancers affect thousands of people annually, with around 40,000 new diagnoses and 16,000 deaths each year in the UK alone. More...

Diagnosing these cancers can be especially difficult in the early stages, as symptoms like fatigue and weight loss are vague and nonspecific. Current diagnostic methods rely on specialized tests such as imaging scans or biopsies, which are often costly, time-consuming, and not readily available in many regions. This lack of accessible and rapid testing limits early detection, which is crucial for successful treatment outcomes. Researchers have now identified certain molecules exhaled in the breath that could indicate the presence of blood cancers, opening the door to a non-invasive, low-cost, and rapid testing alternative.

Researchers from Queen Mary University of London (London, UK) conducted a study using a breathalyser technology called Breath Biopsy, developed by Owlstone Medical (Cambridge, UK). In the trial, the team collected exhaled breath samples from 46 people with blood cancer and 28 healthy individuals. The breath samples were analyzed using mass spectrometry to identify thousands of molecular fragments and establish chemical fingerprints. The study focused particularly on high-grade lymphoma, an aggressive form of blood cancer, and found significantly elevated levels of certain molecules in patients' breath. These molecules are associated with oxidative stress, a process linked to cell damage and cancer development. The goal was to determine whether blood cancer cells release molecules that transfer into the breath, offering a novel detection method.

Published in HemaSphere, the study showed for the first time that breath analysis could help detect blood cancers. The simplicity, portability, and affordability of breathalyser devices offer significant advantages, especially in low-resource settings that lack access to specialized diagnostic infrastructure. These devices could help monitor treatment progress and reduce dependency on expensive scans. Further research will focus on understanding how these airborne molecules are produced and determining which subtypes of lymphoma are most detectable through this method. The team also aims to shorten breath collection times from 10 minutes to just a few seconds and improve the sensitivity and specificity of future breath tests.

“In future, rather than sending patients away for costly scans and waiting for test results, doctors may be able to conduct a quick breath test in their clinic room and potentially have the results within a few seconds,” said Dr. John Riches, lead researcher of the study.

Related Links;
Queen Mary University of London
Owlstone Medical


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.